StreetInsider.com News Articles

Roivant Sciences (ROIV) PT Raised to $36 at Guggenheim

Tue, 26 May 2026 06:38:24 -0400

Guggenheim analyst Yastin Suneja raised the price target on Roivant Sciences (NASDAQ: ROIV) to $36.00 (from $30.00) while maintaining a Buy rating.

Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Venker Eric

Fri, 22 May 2026 18:26:00 -0400

si-local-file:///var/storage/secattach/20260522/26543176.html

Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Venker Eric

Fri, 22 May 2026 18:26:00 -0400

si-local-file:///var/storage/secattach/20260522/26543176.html

Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Pulik Richard

Fri, 22 May 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260522/26543170.html

Form 4 Roivant Sciences Ltd. For: May 20 Filed by: Pulik Richard

Fri, 22 May 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260522/26543170.html

Form 144 Roivant Sciences Ltd. Filed by: Venker Eric

Fri, 22 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26541346.html

Form 144 Roivant Sciences Ltd. Filed by: Venker Eric

Fri, 22 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26541346.html

Roivant Sciences (ROIV) PT Raised at TD Cowen as 'IMVT-1402 Shines In D2T RA'

Thu, 21 May 2026 09:17:38 -0400

(Updated - May 21, 2026 9:17 AM EDT)

TD Cowen analyst Yaron Werber raised the price target on Roivant Sciences (NASDAQ: ROIV) to $41.00 (from $38.00) while maintaining a Buy rating.

The analyst commented: "IMVT-1402 Shines In D2T RA, Many More Catalysts On Deck; IMVT-1402 toplined impressive Ph2b D2T RA data w/ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Brepo in CS received FDA BTD, on track to initiate Ph3 in H2:26. Brepo DM launch in late Sept, with our KOL anticipating bolus at launch. Next catalysts: brepo Ph3 data in NIU & mosli Ph2b data in PH-ILD in H2:26.

Roivant Sciences (ROIV) PT Raised at TD Cowen as 'IMVT-1402 Shines In D2T RA'

Thu, 21 May 2026 09:17:38 -0400

(Updated - May 21, 2026 9:17 AM EDT)

TD Cowen analyst Yaron Werber raised the price target on Roivant Sciences (NASDAQ: ROIV) to $41.00 (from $38.00) while maintaining a Buy rating.

Piper Sandler on Roivant Sciences (ROIV): 'Mosliciguat Ph2 PHocus Takes Center Stage & Catalyst-Rich 2026'

Thu, 21 May 2026 09:00:23 -0400

Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $40.00 price target on Roivant Sciences (NASDAQ: ROIV).

The analyst commented: "Mosliciguat Ph2 PHocus Takes Center Stage & Catalyst-Rich 2026; At earnings, mosliciguat PH-ILD development was a key focus with announcement of Ph2 PHocus (n=135) blinded baseline characteristics that instill high PoS for 2H26 topline. Importantly, mgmt emphasized streamlined execution where early discontinuation rates are consistent with prior PH-ILD studies, >95% of patients reached the maximum dose during titration, and the DMC recommends Ph2 PHocus to continue as planned. Hence, these additional nuggets of detail provide us with strong conviction that

Roivant Sciences (ROIV) PT Raised to $40 at Bernstein SocGen Group

Thu, 21 May 2026 08:55:54 -0400

Bernstein SocGen Group analyst William Pickering raised the price target on Roivant Sciences (NASDAQ: ROIV) to $40.00 (from $35.00) while maintaining a Outperform rating.

H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)

Thu, 21 May 2026 06:37:42 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $34.00 price target on Roivant Sciences (NASDAQ: ROIV).

The analyst commented: "While brepocitinib's success has been the primary driver of Roivant share performance over the last 12 months, the potential for IMVT-1402 has begun to become part of the story. While it felt investors had looked at Roivant with a "glass is half empty" mentality, we've begun to see a shift in sentiment towards thinking the glass may not only be half full, but it may actually be reaching the brim. That shift in sentiment was further bolstered with Roivant, in

Roivant Sciences (ROIV) PT Raised to $42 at Leerink

Thu, 21 May 2026 06:20:33 -0400

Leerink analyst David Risinger raised the price target on Roivant Sciences (NASDAQ: ROIV) to $42.00 (from $38.00) while maintaining a Outperform rating.

The analyst comments "We are raising our DCF-derived PT from $38 to $42, driven primarily by adding the IMVT-1402 D2T-RA indication (2035E risk-adj sales of $1.4B). ROIV showcased compelling data for IMVT-1402 in D2T-RA (difficult-to-treat rheumatoid arthritis) from the ongoing randomized withdrawal trial. IMVT-1402 demonstrated compelling ACR70 responses in heavily refractory patients, including those who had previously failed JAK and TNF therapies. We look forward to IMVT-1402 Period 2 data and initial FDA feedback in 2H26. And we remain

Roivant Sciences (ROIV) PT Raised to $42 at Leerink

Thu, 21 May 2026 06:20:33 -0400

Leerink analyst David Risinger raised the price target on Roivant Sciences (NASDAQ: ROIV) to $42.00 (from $38.00) while maintaining a Outperform rating.

Form S-8 Roivant Sciences Ltd.

Wed, 20 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260520/26529105.html

Form S-8 Roivant Sciences Ltd.

Wed, 20 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260520/26529105.html

Form 10-K Roivant Sciences Ltd. For: Mar 31

Wed, 20 May 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260520/26524771.html

Form 10-K Roivant Sciences Ltd. For: Mar 31

Wed, 20 May 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260520/26524771.html

Form 8-K Roivant Sciences Ltd. For: May 20

Wed, 20 May 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260520/26524757.html

Form 8-K Roivant Sciences Ltd. For: May 20

Wed, 20 May 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260520/26524757.html

Roivant Sciences Ltd. (ROIV) Tops Q4 EPS by 57c

Wed, 20 May 2026 07:08:11 -0400

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q4 EPS of $0.28, $0.57 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $3.76 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Wed, 20 May 2026 07:00:00 -0400

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026

Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026

Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Wed, 20 May 2026 07:00:00 -0400

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026

Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026

Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Wed, 20 May 2026 07:00:00 -0400

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026

Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026

Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Wed, 20 May 2026 07:00:00 -0400

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026

Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026

Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline